Breast Cancer News
Advertisement
Sacituzumab + pembrolizumab improves PFS vs chemo in PD-L1+ TNBC, per ASCENT-04/KEYNOTE-D19 phase 3 trial at ASCO 2025.
Dr. Lustberg discusses DESTINY-Breast09 and the potential shift to T-DXd + pertuzumab in HER2+ mBC first-line treatment.
Stephanie Graff, MD, reviews top ASCO25 breast cancer trials, including ASCENT-04, DESTINY-Breast09, and SERENA-6.
Dr. Gradishar discusses how tolerability, toxicity, and NCCN guidelines shape HER2+ breast cancer treatment decisions.
Dr. William Gradishar discusses treatment sequencing strategies for HER2+ metastatic breast cancer at ASCO 2025.
T-DXd plus pertuzumab significantly improves PFS vs THP in HER2+ mBC, per interim results from DESTINY-Breast09.
Elinzanetant reduces vasomotor symptoms from endocrine therapy in HR+ breast cancer, with rapid onset and good tolerability.
THP delivers similar pCR and better tolerability than TCbHP for HER2+ early breast cancer, per phase 3 neoCARHP trial.
AI-powered TIL analysis may predict pCR and survival outcomes in HR+/HER2– breast cancer treated with neoadjuvant chemo.
High CIG signature or high sTILs linked to better survival in stage I TNBC; findings support further prognostic evaluation.
About 1 in 10 patients with high RS early HR+/HER2- BC decline chemo, which is tied to worse overall survival, per ASCO data.
Imlunestrant improved quality of life and physical function in patients with ER+/HER2– breast cancer in the EMBER-3 trial.
Oral paclitaxel (DHP107) shows non-inferior efficacy and manageable safety vs IV in HER2-negative metastatic breast cancer.
T-DXd improves PFS and cORR over chemo in HER2-low/ultralow HR+ mBC, regardless of PI3K, ESR1, or BRCA1/2 mutations.
Inavolisib + palbociclib + fulvestrant extends OS and delays chemo in PIK3CA-mutant HR+/HER2- advanced breast cancer.
T-DXd rechallenge after grade 1 ILD showed high success and prolonged benefit, with low recurrence and no grade 5 events.
Trastuzumab rezetecan shows strong intracranial activity in HER2+ breast cancer with brain metastases in REIN trial.
Sacituzumab tirumotecan showed a 71% ORR and manageable safety in first-line advanced TNBC, regardless of PD-L1 status.
Dr. Eva Blondeaux discusses RRSO timing and fertility in young BRCA+ women and the need for shared, personalized decisions.
Risk-reducing surgery improves survival in young BRCA1/2 carriers, study shows, guiding counseling for high-risk patients.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.